Below are the ratings of the most accurate analysts for three high-yielding stocks in the health care sector. UBS analyst ...

The initial report of monotherapy with the BCL-2 inhibitor venetoclax showed it had durable clinical activity and favorable ...

Adding polatuzumab vedotin (Polivy) to standard-of-care treatment significantly improved overall survival (OS) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the phase ...

Data from the POLARGO trial potentially establishes a new standard of care for patients with R/R DLBCL ineligible for ...

In a report released today, Peter Lawson from Barclays maintained a Buy rating on Arvinas Holding Company (ARVN – Research Report), with a price target of $16.00. The company’ ...